Ecarin based coagulation testing
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25852
Abstract: Ecarin is derived from venom of Echis carinatus, and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described for decades, but these assays… read more here.
Keywords: coagulation testing; coagulation; ecarin based; based coagulation ... See more keywords
Pulmonary embolism in a morbidly obese patient receiving dabigatran
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22755
Abstract: To the Editor: Dabigatran is a novel oral anticoagulant agent that can be used in fixed-dose regimens for anticoagulation in patients with atrial fibrillation, deep venous thrombosis (DVT), or pulmonary embolism (PE). However, the scientific… read more here.
Keywords: anticoagulation; morbidly obese; pulmonary embolism; obese patients ... See more keywords
[TEG-guided treatment of a dabigatran overdose in a patient with acute kidney failure].
Sign Up to like & getrecommendations! Published in 2020 at "Der Anaesthesist"
DOI: 10.1007/s00101-020-00801-x
Abstract: This article presents the case of a multimorbid male patient with an accidental dabigatran overdose caused by kidney failure in the context of an acute intestinal disorder. After effective initial antagonizing of the dabigatran effect using… read more here.
Keywords: dabigatran overdose; teg; treatment; kidney failure ... See more keywords
How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-018-2571-9
Abstract: To the Editor: Long-term oral anticoagulation is recommended to prevent stroke and systemic embolism in patients with atrial fibrillation (AF) [1]. Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as the preferred choice in these… read more here.
Keywords: atrial fibrillation; long term; dabigatran; total gastrectomy ... See more keywords
Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neurology"
DOI: 10.1007/s00415-018-9011-8
Abstract: Idarucizumab can completely reverse the biological activity of dabigatran within a few minutes [1]. Several reports have documented thrombolytic therapy following antagonism of dabigatran with idarucizumab, and various arrangements have been made in different countries… read more here.
Keywords: plasma dabigatran; dabigatran; concentration; antagonism ... See more keywords
Assessment of patients post reversal with idarucizumab
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-018-1723-1
Abstract: Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran’s anticoagulant activity. Idarucizumab neutralizes the anticoagulant effects of dabigatran by binding to dabigatran and its metabolite. In the full analysis of 503… read more here.
Keywords: reversal; emergent procedure; cohort; dabigatran ... See more keywords
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-019-01986-8
Abstract: Several real-world studies have evaluated adherence to direct acting oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF); however, these studies have not been systematically summarized. We performed a meta-analysis to compare adherence to rivaroxaban… read more here.
Keywords: real world; rivaroxaban; dabigatran; adherence ... See more keywords
Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab
Sign Up to like & getrecommendations! Published in 2017 at "Aging Clinical and Experimental Research"
DOI: 10.1007/s40520-017-0752-5
Abstract: to receive Ibrutinib are elderly and are likely to require anticoagulant or antiplatelet therapy owing to associated comorbidities, including atrial fibrillation and ischemic diseases. Besides, due to the multiple interactions of Ibrutinib with several TKs… read more here.
Keywords: plasma concentration; ibrutinib; increased dabigatran; dabigatran ... See more keywords
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry
Sign Up to like & getrecommendations! Published in 2017 at "American Heart Journal"
DOI: 10.1016/j.ahj.2017.08.018
Abstract: Abstract Background and Purpose GLORIA-AF is a large, global, prospective registry program of newly diagnosed atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the effectiveness and safety of dabigatran etexilate over 2 years… read more here.
Keywords: atrial fibrillation; dabigatran stroke; dabigatran; stroke prevention ... See more keywords
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
Sign Up to like & getrecommendations! Published in 2017 at "Asian journal of surgery"
DOI: 10.1016/j.asjsur.2015.10.007
Abstract: OBJECTIVE In the Re-NOVATE II study, oral dabigatran provided thromboprophylaxis after total hip arthroplasty and improved compliance postdischarge in a global population. This article aims to identify trends (if any) in the Indian population. METHODS… read more here.
Keywords: indian patients; novate study; study; dabigatran ... See more keywords
Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Neurology and Neurosurgery"
DOI: 10.1016/j.clineuro.2019.04.013
Abstract: Idarucizumab is the first Food and Drugs Administration (FDA) approved reversal agent for anticoagulant dabigatran, a direct thrombin inhibitor. Emerging evidence suggests idarucizumab can improve clinical outcome following dabigatran-associated hemorrhage, however, its specific use in… read more here.
Keywords: literature; intracranial hemorrhage; hemorrhage; idarucizumab setting ... See more keywords